Agilent Technologies, Inc. logo A - Agilent Technologies, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 31
HOLD 8
SELL 1
STRONG
SELL 0
| PRICE TARGET: $153.25 DETAILS
HIGH: $165.00
LOW: $140.00
MEDIAN: $152.50
CONSENSUS: $153.25
UPSIDE: 9.65%

Stock News

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

Jul 23, 2026 04:00 AM • businesswire.com
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

Jul 14, 2026 04:00 AM • businesswire.com
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides.

Jul 08, 2026 04:00 AM • businesswire.com
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to.

Jul 01, 2026 04:00 AM • businesswire.com
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ("Agilent", NYSE:A).

Jun 25, 2026 04:06 AM • globenewswire.com
Agilent Completes Acquisition of Biocare Medical

Agilent Completes Acquisition of Biocare Medical

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st.

Jun 25, 2026 04:00 AM • businesswire.com
Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About the Durability of Verra Mobility's Largest Customer Contract and the $35 Million Revenue Hole Left by Avis Budget Group's Termination NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Verra Mobility Corporation (NASDAQ: VRRM) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased VRRM securities between February 24, 2026 and May 26, 2026.

Jun 24, 2026 06:09 AM • prnewswire.com (Hide legal announcements)
Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About Weakening Veterinarian Adoption and Prescription Trends That Cost ZTS Investors $23.91 Per Share Following the Final Disclosure NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Zoetis Inc. (NYSE: ZTS) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026.

Jun 24, 2026 06:09 AM • prnewswire.com (Hide legal announcements)
GPK Deadline Alert: Levi & Korsinsky Reminds Graphic Packaging Holding Company (GPK) Investors of Securities Class Action Deadline on July 6, 2026

GPK Deadline Alert: Levi & Korsinsky Reminds Graphic Packaging Holding Company (GPK) Investors of Securities Class Action Deadline on July 6, 2026

Alert: Claims Focus on Alleged Inventory Mismanagement and Production Curtailments That Drove $130 Million in Projected 2026 EBITDA Losses NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Graphic Packaging Holding Company (NYSE: GPK) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased GPK securities between February 4, 2025 and February 2, 2026.

Jun 24, 2026 06:07 AM • prnewswire.com (Hide legal announcements)
UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING

UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING

Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed strong support for the 21st Century ROAD to Housing Act, comprehensive bipartisan legislation designed to address the nation's housing shortage by expanding supply, reducing costs, and modernizing regulations for manufactured housing.

Jun 24, 2026 02:45 AM • globenewswire.com
Tradeweb Announces Date for Second Quarter 2026 Financial Results

Tradeweb Announces Date for Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, July 30, 2026, at approximately 7:00 AM EDT. In addition, Tradeweb will host a conference call for investors. WHO: Billy Hult, CEO Sara Furber, CFO Ashley Serrao, Head of Treasury, FP&A and IR   WHAT: A discussion of financial results for the second quarter of 2026 followed by a question-and-answ.

Jun 23, 2026 10:00 AM • businesswire.com
The Presidio Group Exclusively Advised Fletcher Jones Automotive Group on the Sale of Porsche, Mercedes-Benz and Audi dealerships in Northern California to AutoNation

The Presidio Group Exclusively Advised Fletcher Jones Automotive Group on the Sale of Porsche, Mercedes-Benz and Audi dealerships in Northern California to AutoNation

FREMONT, Calif.--(BUSINESS WIRE)-- #Audi--The Presidio Group LLC (“Presidio”), an independent merchant banking firm focused on mergers and acquisitions, capital raising and investments in the automotive retail and consumer mobility sectors, exclusively advised Fletcher Jones Automotive Group (“Fletcher Jones”) on the sale of Fletcher Jones Motorcars (Mercedes-Benz) of Fremont, Audi Fremont and Porsche Fremont in Fremont, Calif., and their related real estate, to AutoNation Inc. (“AutoNation”) (“NYSE: A.

Jun 23, 2026 06:20 AM • businesswire.com

Price Targets